An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Recarbrio

Chemical Nameimipenem, cilastatin, and relebactam
Dosage FormInjectable (intravenous; 1.25 g/vial)
Drug ClassInhibitors
SystemUrinary, Digestive
CompanyMerck & Co.
Approval Year2019

Indication

  • Recarbrio is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of the following infections caused by susceptible gram-negative bacteria: complicated urinary tract infections, including pyelonephritis, and complicated intra-abdominal infections.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Recarbrio (imipenem, cilastatin, and relebactam) Prescribing Information 2019Merck
Document TitleYearSource
Carbapenems vs alternative antibiotics for the treatment of complicated urinary tract infection. 2020Medicine (Baltimore)
Carbapenems vs tigecycline for the treatment of complicated intra-abdominal infections: a bayesian network meta-analysis of randomized clinical trials. 2019Medicine (Baltimore)